Stocks · News reference
Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy
Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Annexon Announces Presentations On Vonaprument For Geographic Atrophy At Retina Society Meeting; Says Phase 3 Results Expected In Q4 2026
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgrades Annexon (NASDAQ:ANNX) from Market Underperform to Market Perform.